Tadalafil Tablet, Film Coated
Product Images NDC 63629-8409

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 63629-8409). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl636298409)

Tadalafil 2.5 mg film-coated tablet label by Bryant Ranch Prepack. The label includes storage instructions (store at 20°-25°C), a comparison to Cialis 2.5 mg tablets, NDC 63629-8409, and a barcode. The dosage form is oral and the package size indicated is 90 tablets.*

FDA Label Image

Figure (Tadalafil Figure1)

Four line graphs displaying the difference in blood pressure (Tadalafil minus Placebo) over time up to 96 hours. The graphs show standing systolic BP, standing diastolic BP, supine systolic BP, and supine diastolic BP, with values plotted as mean difference and error bars indicating variability.*

FDA Label Image

Figure (Tadalafil Figure2)

Two line graphs depicting changes in systolic blood pressure (mmHg) over a 24-hour period post-dose. The top graph shows standing systolic blood pressure changes, and the bottom graph shows supine systolic blood pressure changes. Two treatment groups are compared: Tadalafil 20 mg with doxazosin 8 mg (solid line) and placebo with doxazosin 8 mg (dotted line). The x-axis represents time post-dose in hours.*

FDA Label Image

Figure (Tadalafil Figure3)

A line graph depicting systolic blood pressure (mmHg) over 12 hours after administration of tadalafil or placebo with doxazosin at 8 mg. The graph compares blood pressure changes at 08:00 and 20:00 dosing times for 20 mg tadalafil versus placebo, showing fluctuating blood pressure trends for each treatment and time point.*

FDA Label Image

Figure (Tadalafil Figure4)

A line graph displaying plasma tadalafil concentration (µg/L) over time (hours) after different dosing regimens: a single 20-mg dose, a single 5-mg dose, and once-daily 5-mg dosing following 5 consecutive days. The y-axis shows concentration from 0 to 500 µg/L, and the x-axis spans 0 to 120 hours. Error bars indicate variability at each time point.*

FDA Label Image

Figure 5 (Tadalafil Figure5)

Line graph showing change from baseline in IPSS Total Score over 12 weeks of treatment for tadalafil 5 mg versus placebo. The graph plots duration of treatment in weeks on the x-axis and change in score on the y-axis, with tadalafil showing a greater decrease in score compared to placebo over time.*

FDA Label Image

Figure 6 (Tadalafil Figure6)

A line graph showing the change from baseline in IPSS Total Score over a 12-week treatment period. It compares tadalafil 5 mg and placebo, plotting the change in score on the vertical axis against the duration of treatment in weeks on the horizontal axis. The graph includes data points at weeks 0, 1, 4, 8, and 12 with trends indicating greater score reduction for tadalafil compared to placebo.*

FDA Label Image

Figure 7 (Tadalafil Figure7)

A line graph showing changes in least squares (LS) mean from baseline over 26 weeks of therapy comparing Tadalafil/Finasteride and Placebo/Finasteride groups. The x-axis represents weeks of therapy (0, 4, 12, 26), and the y-axis shows LS mean change from baseline, ranging from 0 to -7. Tadalafil/Finasteride shows a greater decline early and sustained difference compared to Placebo/Finasteride, with statistical significance indicated at multiple points.*

FDA Label Image

Figure 8 (Tadalafil Figure8)

A line graph comparing change from baseline in IPSS total score over 12 weeks of treatment between tadalafil 5 mg and placebo groups. The x-axis represents duration of treatment in weeks, and the y-axis shows change in score. Two lines depict trends, with tadalafil showing a greater decrease in IPSS score over time compared to placebo, marked with a statistical significance star at 12 weeks.*

FDA Label Image

Chemical Structure (Tadalafil Structure)

Chemical structure diagram of tadalafil, showing its molecular framework with characteristic rings and functional groups as found in the active ingredient tadalafil.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.